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Allergic asthma is a chronic inﬂammatory respiratory disease associated with
eosinophilic
inﬁltration,
increased
mucus
production,
airway
hyperresponsiveness, and airway remodeling. Epidemiologic data reveal that
the prevalence of allergic sensitization and associated diseases has increased in
the twentieth century. This has been hypothesized to be partly due to reduced
contact with microbial organisms (the hygiene hypothesis) in industrialized
society. Airway epithelial cells, once considered a static physical barrier
between the body and the external world, are now widely recognized as
immunologically active cells that can initiate, maintain, and restrain
inﬂammatory responses, such as those that mediate allergic disease. Airway
epithelial cells can sense allergens via expression of myriad Toll-like receptors
(TLRs) and other pattern-recognition receptors. We sought to determine
whether the innate immune response stimulated by a combination of
Pam2CSK4 (“Pam2”, TLR2/6 ligand) and a class C oligodeoxynucleotide
ODN362 (“ODN”, TLR9 ligand), when delivered together by aerosol
(“Pam2ODN”), can modulate the allergic immune response to allergens.
Treatment with Pam2ODN 7 days before sensitization to House Dust Mite
(HDM) extract resulted in a strong reduction in eosinophilic and lymphocytic
inﬂammation. This Pam2ODN immunomodulatory effect was also seen using
Ovalbumin (OVA) and A. oryzae (Ao) mouse models. The immunomodulatory
effect was observed as much as 30 days before sensitization to HDM, but
ineffective just 2 days after sensitization, suggesting that Pam2ODN
immunomodulation lowers the allergic responsiveness of the lung, and
reduces the likelihood of inappropriate sensitization to aeroallergens.
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Furthermore, Pam2 and ODN cooperated synergistically suggesting that this
treatment is superior to any single agonist in the setting of allergen
immunotherapy.
KEYWORDS

toll-like receptors, allergic asthma, allergen immunotherapy, innate immunity, lung
epithelial cells, allergen tolerance

Introduction

results in protective host resistance to bacteria, fungi, and
viruses (Clement et al., 2008; Tuvim et al., 2009a; Evans et al.,
2010; Duggan et al., 2011). Pam2ODN-mediated pathogen
resistance is initiated very rapidly and has been shown to be
mediated by lung epithelial cells (Cleaver et al., 2014).
More recently, we showed that Pam2ODN can attenuate
chronic asthma-like lung disease in mice infected with Sendai
virus (SeV) (Goldblatt et al., 2020). As hypothesized, Pam2ODN
exerted a strong protective effect against the chronic disease by
reducing the viral burden in the acute infection. However, we also
observed efﬁcacy when Pam2ODN treatment was delivered
outside the time range when reduction in viral burden could
account for the anti-allergic effect. This apparent dissociation
between the reduction in viral burden and chronic disease
severity led us to hypothesize that Pam2ODN also modulated
the type 2 immune response to the viral infection that drives the
chronic inﬂammatory disease.
To disentangle antimicrobial and immunomodulatory effects
of Pam2ODN, we present data here from allergic models where
pathogen killing is irrelevant. In this study, we show that
Pam2ODN attenuates the type 2 allergic immune response to
HDM, Ovalbumin (OVA), and Aspergillus oryzae (Ao) in the
lung mucosa.

Epidemiologic data demonstrate that the prevalence of
allergic sensitization and associated diseases has increased in
the 20th century. This has been hypothesized to be partly due to
reduced contact with microbial organisms (the hygiene
hypothesis) in industrialized society (Lambrecht and
Hammad, 2017). In one study comparing Amish and
Hutterite children, higher levels of microbial elements in farm
dust were found to be strongly protective against developing
asthma (Stein et al., 2016). In mechanistic studies, this effect was
found to be mediated by downregulation of inﬂammatory
pathways within airway epithelial cells (Schuijs et al., 2015).
Allergic inﬂammation is the principle driving force behind
diseases such as asthma, rhinitis, and dermatitis (Hammad and
Lambrecht, 2021). Across these allergic diseases, eosinophilic
inﬁltration in tissues and epithelial responses to IL-13 are
consistently observed, frequently in manifestations that are
highly dependent on tissue-speciﬁc cellular differentiation.
Airway epithelial cells, once considered static physical
barriers between the body and the external world, are now
widely recognized as immunologically active cells that can
initiate, maintain, and restrain inﬂammatory responses, such
as those that mediate allergic disease (Hammad and
Lambrecht, 2021). Lung airway epithelial cells express
myriad pattern recognition receptors (PRRs) such as Tolllike receptors (TLRs) that enable them to sense and respond to
a variety of external triggers, usually referred to as pathogenassociated molecular patterns (PAMPs). The epithelialderived cytokines IL-33, thymic stromal lymphopoietin
(TSLP), and IL-25 are widely recognized as alarmins
produced in response to allergens, such as those associated
with house-dust mites (HDM). These cytokines activate
leukocytes involved in allergic inﬂammation, such as
eosinophils, T helper 2 (TH2) cells, mast cells, basophils,
type 2 innate lymphoid cells (ILC2), and dendritic cells
(DC), which work together to polarize the immune
response in a type 2 direction.
Our group has studied means of stimulating lung epithelial
cells to defend against microbial pathogens (Evans et al., 2011).
We have shown that a combination of Pam2CSK4 (“Pam2”, a
TLR2/6 ligand) and a class C oligodeoxynucleotide ODN362
(“ODN”, a TLR9 ligand), when delivered together by aerosol
(“Pam2ODN”) synergistically activate an innate immune
response in the lung mucosa (but not systemically) which
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Results
Pam2ODN prevents allergic inﬂammation
to HDM
Mice were sensitized by airway instillation of 100 μg HDM
extract at day 0, followed by 6 daily challenges of 10 μg HDM
extract from day 7–12, and evaluation of allergic inﬂammation
on day 15 (Figure 1A) (Willart et al., 2012). As previously
reported, HDM-sensitized, HDM-challenged (HDM/HDM)
mice exhibited robust allergic inﬂammation, though PBSsensitized,
HDM-challenged
(PBS/HDM)
did
not
(Supplementary Figure S1). Allergic inﬂammation to HDM
was reﬂected by the substantial inﬂux of eosinophils
(Figure 1G, orange arrowhead) and lymphocytes (Figure 1G,
black arrowhead) with small numbers of neutrophils (Figure 1G,
blue arrowhead). Macrophages were increased only slightly in
number but were observed to be larger and more intensely
stained than PBS/PBS, indicating activation (Figure 1G, open
arrowhead).
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FIGURE 1
Exposure to Pam2-ODN attenuates allergic inﬂammation to HDM. (A) HDM experimental paradigm with a sensitization of 100 µg HDM and
challenges of 10 µg HDM. In these studies, a single treatment of Pam2ODN was delivered by aerosol as described, 30-, 15-, and 7-days before initial
HDM sensitization to naïve mice. (B) Leukocytes obtained by lung lavage were pelleted onto glass slides by centrifugation and stained with WrightGiemsa. Scale bar = 20 μm. (C–F) Quantiﬁcation of leukocytes in lung lavage for (C) eosinophils, (D) lymphocytes, (E) macrophages, and (F)
neutrophils (N = 3-5 mice). (G–H) Airways stained with H&E to demonstrate submucosal inﬂammation. Scale bar = 40 μm (I) Airway epithelium
stained with PAFS to demonstrate intracellular mucin in red. Scale bar = 20 μm. (J) Quantiﬁcation of intracellular mucin content by image analysis of
airway (N = 3-5 mice). Bars show mean +/- SEM. P* < 0.05 by one-way ANOVA with Dunnett’s test for multiple comparisons against [HDM/HDM]
control. p = PBS. H = HDM.
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FIGURE 2
Pam2-ODN prevents sensitization to HDM. (A,G) Quantiﬁcation of leukocytes in lung lavage when a single Pam2-ODN treatment was
administered before or after sensitization to HDM (N = 3-5 mice). (B,H) Quantiﬁcation of lung leukocytes when 6 consecutive daily Pam2-ODN
treatments were administered after sensitization to HDM during the ﬁrst week (days +1:6) or concurrently with challenge (days +7:12). Quantiﬁcation
of leukocytes in lung lavage for (C,I) eosinophils, (D,J) lymphocytes, (E,K) macrophages, (F,L) neutrophils. Pictograms show blue bar at the
approximate range of Pam2-ODN exposure in relationship to sensitization and challenge. Bars show mean +/- SEM. P* < 0.05 by one-way ANOVA
with Dunnett’s test for multiple comparisons against [HDM/HDM] control. p = PBS. H = HDM.

On H&E staining of lung tissue, most of the inﬁltrating
leukocytes were localized to the submucosal space between
major airways and vasculature, though some alveolar
inﬂammation
was
also
observed
(Figure
1J,
Supplementary Figure S2F). Mucous metaplasia of lung
epithelial cells was assessed by staining lung tissue with
ﬂuorescent PAS stain (PAFS) (Figure 1H) (Piccotti et al.,
2012). Quantitative image analysis of intracellular mucin
content revealed that intracellular mucin accumulates
moderately in PBS/HDM mice despite the near-complete
absence of inﬂammatory leukocytes, though HDM
sensitization was required for the full phenotype
(Figure 1I). A single Pam2ODN treatment 7 days before

When mice were treated with a single Pam2ODN treatment
7 days before HDM sensitization, we observed large reductions in
leukocytes collected in lung lavage ﬂuid, compared to HDM/
HDM mice (Figure 1B). Differential cell quantiﬁcation with
Wright-Giemsa stain revealed a >90% decrease in eosinophils
(Figure 1C), >85% decrease in lymphocytes (Figure 1D), >30%
decrease in macrophages (Figure 1E), and >95% decrease in
neutrophils (Figure 1F). Pam2ODN treatments similarly showed
efﬁcacy when administered 30- and 15-days before sensitization,
with a trend toward less efﬁcacy when the time between
treatment and sensitization was increased. This trend is best
observed when leukocyte quantiﬁcation of multiple experiments
is combined (Supplementary Figures S2A–E).
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administered alone, but the combination Pam2ODN
treatment
completely
blocked allergic inﬂammation
(Figures 3A–E).

HDM sensitization reduced intracellular epithelial mucin
content >35%.

Pam2ODN blocks sensitization to HDM in
the airway

Pam2ODN attenuates allergic
inﬂammation to OVA

We next evaluated whether Pam2ODN prevented
sensitization to HDM or attenuated allergic inﬂammation
during the challenge phase. To do this, we varied the timeinterval and the relative chronological order of Pam2ODN
treatment and HDM sensitization. When Pam2ODN
treatment was administered just 1 day before HDM
sensitization, eosinophils were still signiﬁcantly reduced, but
this effect was completely absent when treatment was
administered just 2 days after HDM sensitization, and at
any later time point (Figures 2A–F). Since multiple
treatments of Pam2ODN had higher efﬁcacy than a single
treatment (Supplementary Figure S3), we evaluated whether
the lack of Pam2ODN efﬁcacy after HDM sensitization
could be due to insufﬁcient treatment by administering
6 daily Pam2ODN treatments after HDM sensitization.
As was observed using single treatments, multiple
treatments after HDM sensitization did not reduce
allergic inﬂammation (Figures 2G–L).
Historically, most preclinical investigation of allergic disease
has been carried out using OVA. This model differs signiﬁcantly
from HDM because sensitization occurs intraperitoneally,
followed by airway mucosal challenge. To better establish the
breadth of the anti-allergic effects of Pam2ODN, we also
evaluated whether Pam2ODN could prevent airway allergic
inﬂammation in the setting of systemic HDM sensitization
occurring at a different location than the lungs. To do this,
we used the same time schedule for HDM sensitization and
challenge as previously shown, except that HDM sensitization
was performed by intraperitoneal injection of 100 μg HDM
(Supplementary Figure S4A). Pam2ODN treatments were
administered at day 0 and day 6 to cover the entire challenge
period, however this resulted in no signiﬁcant reduction in
allergic inﬂammation (Supplementary Figures S4B–E).

To evaluate the generalizability of Pam2ODN allergic
immunomodulation, we also tested a conventional 3-week
OVA model (Figure 4A), consisting of 2 sensitizing
intraperitoneal injections during the ﬁrst week, and aerosol
challenges beginning on day 8 administered every 2–3 days
until day 21. From day 21 to day 24, OVA aerosol challenges
were given daily, and allergic inﬂammation was assessed at day
24. Pam2ODN treatments were given immediately before OVA
challenges. OVA-sensitized, OVA-challenged (OVA/OVA) mice
had elevated leukocytes, compared to PBS-sensitized, OVAchallenged (PBS/OVA) mice (Figure 4B). Pam2ODN
treatment reduced eosinophils >75% (Figure 4C), but
macrophages (Figure 4E) and lymphocytes (Figure 4D) were
unchanged. With this Pam2ODN treatment model, neutrophils
were observed to be elevated (Figure 4F), however this is likely a
direct response to Pam2ODN, which elicits neutrophilic
inﬂammation over a period of 72 h, rather than a secondary
effect on the allergic response (Alfaro et al., 2014). Airway
epithelial mucin content was also decreased >25% by
Pam2ODN treatment (Figure 4L).
Assessing changes in the systemic immune response,
Pam2ODN treatment reduced serum immunoglobulin E (IgE)
levels by >50% (Figure 4G), including a strong trend towards
reducing OVA-speciﬁc IgE levels (Figure 4H), but total IgG
(Figure 4I) and IgG1 (Figure 4J) were unchanged. IgG2a
levels, which increase with type 1 immune responses,
decreased in OVA/OVA mice, compared to PBS/PBS, and
Pam2ODN treatment reversed this change (Figure 4K).

Pam2ODN attenuates allergic
inﬂammation to Aspergillus oryzae
Allergic sensitization can occur following exposure to
fungal antigens (Pashley and Wardlaw, 2021). Extending
our investigations more broadly, we evaluated whether
fungal allergic inﬂammation could also be attenuated by
Pam2ODN, testing a combined Ao-OVA (AoO) model
(Figure 5A), with a similar time schedule as with OVA
alone (Figure 4A), except Ao-OVA or Pam2ODN were not
administered from days 21–24, to avoid confounding by acute
neutrophilic inﬁltration caused by the fungal elements or the
Pam2ODN at the time of assessment. Pam2ODN treatment
caused a signiﬁcant reduction in inﬂammation (Figure 5B),
predominantly due to a >50% reduction in eosinophils (Figure

Pam2 and ODN interact synergistically
The ligands Pam2 and ODN were selected for their
remarkable synergy, and their dosing was established based on
maximal pneumonia-protective effect, (Alfaro et al., 2014),
however this characteristic has only been evaluated for
antimicrobial resistance thus far (Duggan et al., 2011). To
evaluate whether Pam2 and ODN also cooperate for allergic
immunomodulation, the agonists were aerosolized individually
or in combination 7 days before HDM sensitization. Neither
Pam2 nor ODN exhibited any signiﬁcant efﬁcacy when
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FIGURE 3
Pam2 and ODN interact synergistically to block sensitization to HDM. Pam2, ODN, or Pam2ODN was administered 7 days before sensitization
to HDM. Pam2 and ODN treatments were performed in an identical manner and at identical concentrations as Pam2ODN treatments throughout.
Quantiﬁcation of leukocytes in lung lavage for (A) total leukocytes (B) eosinophils, (C) lymphocytes, (D) macrophages, and (E) neutrophils (N = 35 mice). Bars show mean +/- SEM. P* < 0.005 for synergy between Pam2 and ODN by linear regression. p = PBS. H = HDM.

the degree of type 2 polarization. Our results suggest that the lack
of clinical success with these agents may be due to the fact that the
immunomodulatory efﬁcacy of aerosolized TLR agonists is far
greater when given prior to allergic stimulation rather than after.
Therefore these agents may only be useful when given
prophylactically at a young age to subjects at high risk for
allergic asthma, rather than to subjects with established
allergic asthma. In addition, prior evidence that TLR agonists
can interact synergistically suggests that single agents may not
offer optimal efﬁcacy.
In an earlier study, we found that Pam2ODN had
immunomodulatory effects on the chronic asthma-like disease
that persists after SeV viral clearance that could not be explained
by Pam2ODN-mediated antiviral properties (Goldblatt et al.,
2020). In the current study, we observed Pam2ODN was broadly
effective at reducing allergic inﬂammation and mucous
metaplasia induced by three different allergens: HDM, OVA,
and Ao. While each model displays unique immunogenic
characteristics, SeV, HDM, OVA, and Ao all lead to a chronic
lung disease driven by polarization of the lung mucosa towards
type 2 immunity. The effectiveness of this treatment against all
antigens evaluated, as well as the immunomodulatory effects on

5C). Macrophages were decreased in AoO-challenged mice,
and this was reversed by Pam2ODN treatment (Figure 5D).
Lymphocytes were not signiﬁcantly elevated in AoO
challenged mice, compared to mice only challenged with
PBS (Figure 5E). Neutrophil levels were not increased in
Pam2ODN-treated groups (Figure 5F) due to the removal
of Pam2ODN treatments within 3 days of evaluation. Airway
epithelial mucin content was also observed to be
decreased >30% with Pam2ODN treatment (Figure 5G).

Discussion
Over the last two decades, scientiﬁc interest in utilizing PRR
agonists, particularly TLRs, for the development of novel, rapidonset immunotherapy has grown considerably (Kirtland et al.,
2020). However, these agents have not yet achieved signiﬁcant
clinical success, as exempliﬁed by a recent study of a
TLR9 agonist that failed to improve asthma control (Psallidas
et al., 2021). The inability to translate preclinical success into
clinical results is likely due to the complexity of allergic
sensitization and the interplay of different variables affecting
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FIGURE 4
Exposure to Pam2-ODN attenuates allergic inﬂammation to OVA. (A) OVA experimental paradigm with sensitization of 20 µg OVA by
intraperitoneal injection and aerosol challenges of 2.5% OVA. (B–F) Quantiﬁcation of leukocytes in lung lavage for (B) total leukocytes (C)
eosinophils, (D) lymphocytes, (E) macrophages, and (F) neutrophils (N = 4-5 mice). (G–J) Quantiﬁcation of serum immunoglobulin concentrations
by ELISA for (G) IgE, (H) OVA-speciﬁc IgE, (I) IgG, (J) IgG1, and (K) IgG2a (N = 8-9 mice). (L) Quantiﬁcation of intracellular mucin content by
image analysis of airway stained with PAFS (N = 4-5 mice). Bars show mean +/- SEM. p* < 0.05 by unpaired students’ t test for OVA vs. OP-OVA. P =
PBS. OVA = Ovalbumin.

phenotype (Hammad et al., 2009). We further show that lung
epithelial cells can respond to HDM directly and immediately by
the observation that PBS/HDM mice show accumulated
intracellular mucin and no detectable eosinophil recruitment.
This indicates that lung epithelial cells can generate an allergic
response directly and that this can occur before the innate or
adaptive leukocyte-mediated immune responses have developed.
Taken together, these data suggest that integration between the
type 2 immunogens and Pam2ODN immunomodulation takes
place within lung epithelial cells, which are optimally positioned
to be ﬁrst responders to both inputs.
By varying single treatments of Pam2ODN at different time
points before and after HDM sensitization, we were able to show
that Pam2ODN treatment is only effective when administered
before HDM sensitization. We observed Pam2ODN efﬁcacy in as
little as 24 h before sensitization, but a single treatment 2 days
after sensitization was completely ineffective. These results are
congruent with long-standing observations that once the initial

the SeV-induced chronic disease from our previous study,
(Goldblatt et al., 2020), suggests that Pam2ODN is a broadly
effective immunomodulatory agent that can regulate the type
2 immune response. It is notable that the timing of treatments
and readouts varied between models, so no direct inter-model
comparisons are made.
One of the most striking results is the onset speed of
Pam2ODN-induced
immunomodulation,
with
efﬁcacy
observed in as little as 24 h before HDM sensitization.
Leukocyte recruitment to the lung by Pam2ODN has been
measured previously to reach a peak 48 h after exposure to
Pam2ODN (Alfaro et al., 2014), and thus is unlikely to be
responsible for the immunomodulatory effect seen at this
early time point. On the other hand, epithelial cytokine
release following Pam2ODN exposure has been observed
within 4 h (Alfaro et al., 2014). Additionally, it has been well
established that HDM sensing by lung epithelial cells, primarily
via TLR4, is required for the development of the full allergic
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FIGURE 5
Exposure to Pam2-ODN prevents allergic inﬂammation to Aspergillus oryzae. (A) Ao-OVA experimental paradigm with a single aerosol
challenge of 10 µg Ao and 2.5% OVA administered together, and repeated 7 times up for up to 21 days, at a regular interval between treatments.
Pam2ODN was delivered as a separate aerosol treatment immediately before Ao-OVA with dedicated hardware. (B–E) Quantiﬁcation of leukocytes
in lung lavage for (B) total leukocytes (C) eosinophils, (D) lymphocytes, (E) macrophages, and (F) neutrophils (N = 4-9 mice). (G) Quantiﬁcation
of intracellular mucin content by image analysis of airway stained with PAFS (N = 4-9 mice). Bars show mean +/- SEM. p* < 0.05 by unpaired students’
t test for OVA vs. OP-OVA.

strong pro-type 2 adjuvant (i.e., alum). OVA-speciﬁc
lymphocytes are processed and distributed systemically. Upon
subsequent exposure, these OVA-speciﬁc lymphocytes are
restimulated and provide enough pro-type-2 inﬂammatory
stimulus to overcome the anergic threshold in the lung.
Pam2ODN is delivered directly to the airway mucosa via
aerosol and exerts virtually no effect on systemic immune
responses when evaluated in a non-allergic host (Alfaro et al.,
2014). These previous data indicate that any primary action by
Pam2ODN on systemic immune responses is highly implausible.
Because Pam2ODN efﬁcacy was still observed with our OVA
mouse model, it seems possible that in some circumstances,
immunomodulatory therapy can prevent airway polarization
despite the additional type 2 immune stimulus supplied by
antigen-speciﬁc lymphocytes.

threshold for lung anergy has been surpassed, continued
exposures result in continued polarization in a type
2 direction, as a classic positive feedback loop. As the lung
mucosa become progressively polarized, the window for
effective therapeutic intervention diminishes.
Viewing the results from the HDM model in isolation might
lead to a conclusion that Pam2ODN is simply ineffective at any
time after exposure to allergen. However, when considered in
conjunction with the OVA model data, a more reﬁned picture
emerges that suggests Pam2ODN immunomodulation might be
speciﬁcally affecting allergic inﬂammation at the lung mucosa,
and not systemically. Unlike HDM, ovalbumin does not readily
result in allergic airway inﬂammation when delivered into the
airways without a preceding sensitizing exposure. To achieve
host sensitization, OVA is injected intraperitoneally along with a
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possible that even greater anti-allergic efﬁcacy could be achieved
by varying the dosing of these two components.
We propose that these data support a stronger focus on
identifying the bi-directional signaling that occurs between
systemic immune responses and mucosal tissues. Identifying these
intercellular and intracellular pathways would enable better rational
design of therapeutically relevant immunomodulatory agents. An
ideal therapeutic strategy might utilize multiple agents that interact
synergistically to maximally oppose any allergic stimuli that might be
encountered. Additionally, we show here that allergic polarization of
mucosal tissues can proceed independently of the systemic immune
system. Taken together, this suggests integration of pro-allergic type2 stimuli and the Pam2ODN immunomodulatory response. Thus, it
is plausible that treatments focused on reducing type 2 polarization of
the mucosal tissue might be as effective as broadly blocking systemic
immune responses (e.g., glucocorticoids), while likely avoiding
toxicities of systemic immunosuppression.
The current study has important limitations that impact its
interpretation. Most notably, the experimental models of allergic
inﬂammation studied (HDM, OVA, Ao) were executed with
differing times between Pam2ODN treatment and the allergic
stimulus. Similarly, the time from allergic stimulus to certain
readouts were not uniform across the models. Finally, some
readouts (e.g., allergen-speciﬁc IgE) were available for some models
but not others. The principle consequence of these differences is
rendering head-to-head comparisons of the inter-model effects of
Pam2ODN inappropriate. The presented data demonstrate desirable
effects of Pam2ODN in all three tested models (as well as in previously
in SeV-induced allergic inﬂammation [REFS]), but the current work
does not establish that the mechanisms are the same between the
models. Indeed, the efﬁcacy of Pam2ODN in preventing or
attenuating allergic inﬂammation does appear to vary temporally
between models. These differences are an active area of investigation.
In conclusion, we have shown that Pam2ODN is a generalizable
immunomodulatory agent that counteracts allergic type 2 immune
responses caused by a wide variety of immunogens and is likely
superior to previously tested single agents, due to synergistic
cooperation. The public need for immunomodulatory agents that
can counteract the morbidity of type 2 allergic disease is great, and
clinical studies with Pam2ODN have already shown the drug to be
well tolerated in humans (NCT04313023, NCT04312997,
NCT03794557,
NCT02566252,
NCT02124278),
allowing
Pam2ODN to be efﬁciently evaluated in the setting of allergic
immunotherapy.

Interestingly, we also observed an overall change toward less
systemic immunity to OVA in Pam2ODN-treated mice, reﬂected
by lower levels of total IgE, OVA-speciﬁc IgE and IgG2a. This
suggests that airway immunomodulation during repeat
exposures to allergen may attenuate systemic re-sensitization
and further polarization. Over time, this might enable the host
immune system to redevelop a normal anergic state without
continually being re-sensitized. If so, it is possible that an
extended period of treatment with Pam2ODN might prevent
the progression of atopic sensitivity.
We also demonstrate that the immunogenicity of systemically
sensitized leukocytes can vary signiﬁcantly, and if sufﬁciently strong,
can overcome the Pam2ODN-induced immunomodulation. We
developed a novel adaptation of the acute HDM model based on
intraperitoneal injection of HDM extract, followed by airway HDM
challenges. Unlike our observations with the OVA model,
Pam2ODN airway immunomodulation was ineffective at
preventing airway allergic polarization. One possible explanation
for this discord is that HDM is intrinsically a stronger type
2 immunogen than OVA, and that the HDM-speciﬁc T cells
provide a stronger pro-Th2 stimulus than OVA-speciﬁc T cells.
In this setting, the strength of Pam2ODN immunomodulation as a
counter-regulatory stimulus is insufﬁcient to prevent a shift to type
2 polarization. HDM immunogenicity strength is further supported
by the previous observations that HDM extract is capable of
sensitizing hosts directly in the lung mucosa and does not
require adjuvant pairing. This hypothesis will be explicitly tested
in future work.
Because different allergens appear to have different immunogenic
strength, it is plausible that effective immunomodulation of strong
immunogens require equivalently strong immunomodulatory
stimulus. Any single PRR agonist will ultimately be restricted by
receptor saturation, and thus cannot invoke a stronger response above
a set threshold concentration. However, Pam2ODN provides an
important clue to bypassing this immunomodulatory strength limit
by pairing immunomodulatory agents that exhibit synergy. Previous
work has shown that Pam2 and ODN cooperate synergistically to
mediate protection against microbial pathogens, suggesting the
importance of coincidence detection of multiple PRRs for innate
immune sensing and generating antimicrobial responses, (Cleaver
et al., 2014), and potentially highlighting a way to increase the strength
of immunomodulatory responses. Our results conﬁrm that synergistic
interaction is also required for Pam2ODN efﬁcacy against
inﬂammation, as neither Pam2 nor ODN showed any efﬁcacy
when delivered alone. We believe this highlights the importance of
evaluating combinations of immunomodulatory agents for future
human studies. While Pam2 and ODN were the strongest
combinations of PRR agonists for antimicrobial efﬁcacy, (Duggan
et al., 2011), a systematic screen has never been performed that
assessed immunomodulatory strength, and it is possible that different
combinations of PRR agonists might show even greater
immunomodulatory strength. Relatedly, the dosing of Pam2 and
ODN were optimized to maximal antimicrobial effects, but it is
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Materials and methods
Mice
Animal studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010). Breeder BALB/cJ mice were
obtained from the Jackson Laboratory (Sacramento, CA) and
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the oropharynx and allowing aspiration into the lungs, with mice
suspended by the upper incisors on a board at 60° from horizontal
under isoﬂurane anesthesia. Mice were then challenged with 10 µg
of HDM by depositing the same volume of reconstituted HDM into
the nasal vestibule. This model and HDM dosages were selected
from previously published data and conﬁrmed by us during pilot
studies (Supplementary Figure S1). In one case, mice were sensitized
to 100 µg of HDM by intraperitoneal injection of 40 ul of
reconstituted HDM. For all experiments, mouse age at the time
of sensitization to HDM was between 6 and 7 weeks old.

housed in speciﬁc pathogen-free conditions on a 12-hour light/dark
cycle with free access to food and water. For euthanasia, mice were
injected intraperitoneally with 2,2,2-tribromoethanol (250 mg/kg)
and exsanguinated by transection of the abdominal aorta. For all
mouse experiments, all subjects in a cohort were of the same sex.
Each experiment was repeated a minimum of 3 times. For each
experiment, at least one replicate performed with each sex. We did
not observe any signiﬁcant differences between sex in our study,
though this approach was not powered to exclude the possibility of
very subtle differences. All procedures were performed in
accordance with the Institutional Animal Care and Use
Committee of MD Anderson Cancer Center and the Texas
A&M Institute for Biosciences and Technology. Chemicals were
obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise
speciﬁed.

Sensitization and airway challenge
with OVA
Mice were sensitized to 20 g ovalbumin (OVA) (Grade V,
2.25 mg alum in saline, pH 7.4; Sigma, St. Louis, MO) by
intraperitoneal (i.p.) injection on day 0 and 7. Sensitized mice
were exposed for 30 min to an aerosol of 2.5% (wt/vol)
ovalbumin in PBS, using an Aerotech II nebulizer, as described
above.

Treatment with aerosolized Pam2ODN
This was performed as described (Alfaro et al., 2014). Brieﬂy,
ODN 5′ TCG TCG TCG TTC GAA CGA CGT TGA T 3’ as the
sodium salt on a phosphorothioate backbone (ODN M362) was
purchased from TriLink BioTechnologies (San Diego, CA) and 2,3bis
(palmitoyloxy)-2-propyl-Cys-Ser-Lys-Lys-Lys-Lys-OH
(Pam2CSK4) as the triﬂuoroacetic acid salt was purchased from
Peptides International (Louisville, KY). A solution of ODN (1 μM)
and Pam2CSK4 (4 μM) in endotoxin-free sterile water (8 ml) was
placed in an Aerotech II nebulizer (Biodex Medical Systems, Shirley,
NY) driven by 10 L/min of 5% CO2 in air to promote deep
breathing. The nebulizer was connected by polyethylene tubing
(30 cm × 22 mm) to a 10-L polyethylene chamber vented to a
biosafety hood. Mice were exposed to the aerosol for 20 min,
resulting in the nebulization of ~4 ml of O/P solution. The
optimal molar ratio between Pam2 and ODN was previously
determined (Evans et al., 2011). The dosage of Pam2ODN was
chosen to reﬂect the upper shoulder of secreted epithelial cytokines,
leukocyte recruitment, and anti-microbial efﬁcacy by dose-response
experiments (Alfaro et al., 2014). The dosage, route, and overall
process of administering a Pam2ODN treatment was standardized
across every experiment in the study. The only variation to
Pam2ODN treatment occurs in the studies measuring additivity
and synergy of the independent ligands, whereby some groups
received only ODN or only Pam2 components in the nebulized
solution, but other wise were administered in exactly the same way
and at the same ﬁnal concentrations as the combined solution.

Airway challenge with Aspergillus oryzae
and OVA
Aspergillus oryzae protease (Sigma-Aldrich, St. Louis, MO) was
resuspended in PBS. Mice were challenged with 10 ug A. oryzae and
2.5% (wt/vol) OVA by aerosol 2.5 times per week for 3 weeks. A.
oryzae dose was selected from previously published data (Morgan
Knight et al., 2018). Aerosol challenge was performed as described
above for OVA.

Bronchoalveolar lavage and differential
leukocyte analysis
This was performed by instilling and collecting two 1 ml
aliquots of ice-cold PBS through a 20 gauge cannula inserted
through rings of the exposed trachea of euthanized animals,
then combining the aliquots as described (Alfaro et al., 2014).
Total leukocyte count was determined using a
hemocytometer,
and
differential
counts
by
cytocentrifugation of 100 μL of lavage ﬂuid at 300 g for
5 min followed by Wright-Giemsa staining.

Sensitization and airway challenge
with HDM

Histochemistry
Lungs were ﬁxed by intratracheal inﬂation with 10% formalin to
20 cm H2O pressure for 12 h, and then embedded in parafﬁn. Tissue
blocks were cut into 5-µm sections, mounted on frosted glass slides
(Medline, Northﬁeld, IL), deparafﬁnized with xylene, washed with

Lyophilized HDM extract (Stallergenes Greer, Lenoir, NC) was
resuspended in PBS. Mice were sensitized to 100 μg of HDM
(protein weight) by depositing 40 μL of reconstituted HDM into
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Ethics statement

ethanol, then rehydrated and stained with hemoxtylin and eosin
(H&E) (Sigma-Aldrich, St. Louis, MO).

The animal study was reviewed and approved by the
IACUC, MD Anderson Cancer Center.

Epithelial mucin content

Author contributions

Epithelial mucin content was measured as described (Evans
et al., 2004; Tuvim et al., 2009b; Piccotti et al., 2012). Lungs were
ﬁxed and processed, as described above, but stained with periodic
acid ﬂuorescent Schiff reagent (PAFS). Left-axial bronchus sections
were obtained using a custom precision cutting instrument (ASI
Instruments, Warren, MI), as previously described (Goldblatt et al.,
2020). Images were acquired by investigators blinded to mouse
treatment, and morphometric analysis of the images for quantitation
of intracellular mucin was performed using MATLAB Software
(Mathworks Software, Natick, MD). Data are presented as the area
of intracellular mucus, normalized to the length of the basement
membrane.

DG, SE, and BD conceived the study; DG wrote the
manuscript; DG created the ﬁgures; DG, GV, SW, VK, ML,
AJ, RC, AF performed the studies.
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DG was a Howard Hughes Medical Institute Medical Research
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Statistical analysis

Conﬂict of interest

All data sets were ﬁrst analyzed with the Shapiro-Wilk test
to determine normality. For analyses where there was only a
single comparison between two groups, data was analyzed by
Student’s t-test or Mann-Whitney U test for normally and
non-normally distributed data, respectively. For analyses
where multiple experimental groups were compared against
a single control, data were ﬁrst analyzed by one-way ANOVA
or ANOVA on ranks to determine if a signiﬁcant difference
between any groups was present for normally and nonnormally distributed data, respectively. If a signiﬁcant
difference was found by ANOVA, data were further
analyzed using Dunnett’s test. For analyses where each
experimental group was compared to every other group,
data were further analyzed using Tukey’s test for one-way
ANOVA or Dunn’s test for all pairwise combinations for
ANOVA on ranks. Signiﬁcance was determined from
adjusted p values. For studies comparing Pam2 and ODN
individually and together, an interaction score from linear
regression analysis was used to determine whether there was a
synergistic effect. All data were analyzed using Prism (version
9, GraphPad Software, San Diego, CA). p < 0.05 was
considered statistically signiﬁcant.
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